Schad MD, Patel AK, Glaser SM, et al. - Brachytherapy utilization over time by health insurance type was examined. Further, whether there is reversion in reported declines in brachytherapy, has been investigated. The National Cancer Database (NCDB) yielded data from 17,442 patients who were diagnosed with FIGO IIB-IVA cervical cancer and were treated with definitive chemoradiotherapy between 2004 and 2014. The analysis revealed a decline in brachytherapy utilization during 2008–10 (52.6%) vs 2004–2007 (54.4%) and declines were disproportionately larger for patients with government insurance (49.4% vs 52.3%, respectively) than privately-insured patients (57.6% vs 58.9%, respectively). However, all insurance groups exhibited recovery in rates of brachytherapy use subsequently during 2011–14 (58.0%); the rates particularly improved for Medicaid and uninsured patients. As government insurance covers vulnerable patient populations at-risk for future declines in brachytherapy use, researchers recommend incentivizing cervical brachytherapy in proposed alternative payment models to improve gains in brachytherapy utilization.